News Releases

More events are coming soon.
- Grifols gains exclusive rights to fostamatinib in all potential indications in Europe and Turkey - Rigel to receive an upfront payment of $30 million, with the potential for $297.5 million in total regulatory and commercial milestones - Potential milestones to Rigel include a $20 million payment
Reports 1,794 total bottles of TAVALISSE™ (fostamatinib disodium hexahydrate) sold in 2018 SOUTH SAN FRANCISCO, Calif. , Jan. 7, 2019 /PRNewswire/ --  Rigel Pharmaceuticals, Inc.  (Nasdaq: RIGL) today provided a business update, including the quantity of TAVALISSE™ bottles sold in 2018 and its cash
SOUTH SAN FRANCISCO , Jan. 3, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez , the company's president and CEO, is scheduled to present a company overview at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019 at